Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France)

Pouchieu, Camille; Gruber, A.; Berteaud, Émilie; Ménégon, Patrice; Monteil, Pascal; Huchet, A.; Vignes, Jean‐Rodolphe; Vital, Anne; Loiseau, Hugues; Baldi, Isabelle

doi:10.1186/s12885-018-4545-9

Cited by 43 publications

(45 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average annual crude incidence rate in this study was calculated to be 0.56/100000 and average age adjusted incidence rate calculated in this study was 1.19/100,000 which is much lower in comparison to the overall incidence of 7.08/100000 reported by CBTRUS and the range of 2.1-5.8 /100,000 incidence rate of primary brain tumors observed in various studies [ 6 , 20 ] . The calculated incidence rate also appears to be lower than the age adjusted incidence rate of the New Zealand Cancer Registry and Gironde Cancer Registry (6.7 and 7.4 per 100,000 respectively) [ 2 ]. The incidence rate of primary malignant brain tumors in Iran was recorded as 2.74/100000 which is lower than seen in other developed countries [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…More than 90% of the primary CNS tumors arise in the brain, the remainder are observed in the meninges, spinal cord and cranial nerves [1]. There are more than a hundred histologic subtypes of primary brain tumors [2]. Primary brain tumors are relatively rare, particularly in adults; however, they are the second highest cause of cancer mortality in people under 19 years of age [2].…”

Section: Introductionmentioning

confidence: 99%

“…There are more than a hundred histologic subtypes of primary brain tumors [2]. Primary brain tumors are relatively rare, particularly in adults; however, they are the second highest cause of cancer mortality in people under 19 years of age [2]. Primary brain tumors may range from being benign to aggressive; nevertheless, even benign tumors are potentially lethal.…”

Section: Introductionmentioning

confidence: 99%

“…Gliomas are the most common histological type of primary CNS tumors [1]. Increasing incidence of brain tumors has been attributed to improved ability to diagnose brain tumors using computerized tomography scanning and magnetic resonance imaging [2].…”

Section: Introductionmentioning

confidence: 99%

“…Brain tumors are somewhat uncommon considering one individual in 165 will be diagnosed with a brain tumor in their lifetime [ 4 ]. However, trends from 1970s onwards have shown an increased diagnosis of brain tumors in developed countries, with a world age standardized incidence rate that ranges from 4.3 to 18.6 per 100,000 per year [ 2 , 5 ]. Gliomas are the most common histological type of primary CNS tumors [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study

2020

View full text Add to dashboard Cite

Background: Cancer is the third leading cause of death in the United Arab Emirates (UAE); brain cancer ranks 10th among the cancers, with 2.9% of the primary cancers originating from the nervous system. The epidemiology of brain cancers has not been explored. The unique population dynamics of UAE make it a fertile ground for analyzing the epidemiology of brain cancer. In this study, we aim to look at the frequency patterns and distribution of malignant primary brain tumors in the UAE. Methods: A cross sectional study was carried out using data obtained from the Tawam Hospital Cancer Registry for the years 1984-2017. The sample size included 756 diagnosed cases of malignant primary brain tumors in the UAE. Using SPSS and Excel software, frequencies, mean ages, histological type frequencies, average annual crude incidence rates and average annual age adjusted incidence rates were analyzed. Results: The expatriate population had higher percentage of brain tumors (72%) than the locals. The mean age at diagnosis was 33.48 years (± 21.14 years) with a male to female ratio of 1.69. Diffuse astrocytic and oligodendroglial tumors were the most commonly diagnosed tumors overall. Older adults had more cases of lymphoma while embryonal and ependymal tumors were most commonly seen in younger age groups. The overall average annual crude incidence rate for 2013-2016 for all primary brain tumors was 0.56 per 100,000 population. Conclusion: This is the first cancer registry study in the UAE that describes histological types of primary brain tumors based on the WHO 2016 classification of brain tumors and highlights their incidence rates. Through this study, several patterns of incidence trends for brain tumors in the UAE, according to histological types, sex and age groups have been recognized. Comparative studies would help identify the influence of potential changes in lifestyle, environmental or occupational risk factors on primary brain tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study

2020

View full text Add to dashboard Cite

show abstract

Nonmalignant meningioma and vestibular schwannoma incidence trends in the United States, 2004‐2017

Withrow

Devesa

Deapen

et al. 2021

Cancer

View full text Add to dashboard Cite

Background Given concerns about risks associated with the growing use of mobile phones over recent decades, the authors analyzed temporal trends in incidence rates of nonmalignant meningioma and vestibular schwannoma in the United States. Methods The incidence of nonmalignant meningioma and vestibular schwannoma among adults in the Surveillance, Epidemiology, and End Results 18 registries during 2004 through 2017 was evaluated according to the method of diagnosis: microscopically (MC) or radiographically confirmed (RGC). Annual percent changes (APCs) and 95% CIs were estimated using log‐linear models. Results Overall meningioma rates (n = 108,043) increased significantly from 2004 to 2009 (APC, 5.4%; 95% CI, 4.4%‐6.4%) but subsequently rose at a slower pace through 2017 (APC, 1.0%; 95% CI, 0.6%‐1.5%). Rates for MC meningiomas changed little from 2004 to 2017 (APC, −0.3%; 95% CI, −0.7%, 0.1%) but rose rapidly for RGC meningiomas until 2009 (APC, 9.5%; 95% CI, 7.8%‐11.1%) and rose more modestly thereafter (APC, 2.3%; 95% CI, 1.5%‐3.0%). Overall vestibular schwannoma rates (n = 17,475) were stable (APC, 0.4%; 95% CI, −0.2%, 1.0%), but MC vestibular schwannoma rates decreased (APC, −1.9%; 95% CI, −2.7%, −1.1%), whereas RGC vestibular schwannoma rates rose (2006‐2017: APC, 1.7%; 95% CI, 0.5%‐3.0%). For each tumor, the trends by diagnostic method were similar for each sex and each racial/ethnic group, but RGC diagnosis was more likely in older patients and for smaller tumors. Meningioma trends and the proportion of RGC diagnoses varied notably by registry. Conclusions Overall trends obscured differences by diagnostic method in this first large, detailed assessment, but the recent stable rates argue against an association with mobile phone use. Variation among registries requires evaluation to improve the registration of these nonmalignant tumors. Lay Summary The etiology of most benign meningiomas and vestibular schwannomas is poorly understood, but concerns have been raised about whether mobile phone use contributes to risk of developing these tumors. Descriptive studies examining temporal trends could provide insight; however, globally, few registries collect these nonmalignant cases. In the United States, reporting benign meningiomas and vestibular schwannomas became required by law in 2004. This was the first large, systematic study to quantify and characterize incidence trends for meningioma and vestibular schwannoma according to whether the tumors were diagnosed microscopically or only radiographically. Differential trends across registries and by diagnostic method suggest that caution should be used when interpreting the patterns.

show abstract

A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

Pasdaran,

Grice,

Hamedi

2024

Drug Development Research

View full text Add to dashboard Cite

In 2021, the World Health Organization released the fifth edition of the central nervous system (CNS) tumor classification. This classification uses histopathology and molecular pathogenesis to group tumors into more biologically and molecularly defined entities. The prognosis of brain cancer, particularly malignant tumors, has remained poor worldwide, approximately 308,102 new cases of brain and other CNS tumors were diagnosed in the year 2020, with an estimated 251,329 deaths. The cost and time‐consuming nature of studies to find new anticancer agents makes it necessary to have well‐designed studies. In the present study, the pathways that can be targeted for drug development are discussed in detail. Some of the important cellular origins, signaling, and pathways involved in the efficacy of bioactive molecules against CNS tumorigenesis or progression, as well as prognosis and common approaches for treatment of different types of brain tumors, are reviewed. Moreover, different study tools, including cell lines, in vitro, in vivo, and clinical trial challenges, are discussed. In addition, in this article, natural products as one of the most important sources for finding new chemotherapeutics were reviewed and over 700 reported molecules with efficacy against CNS cancer cells are gathered and classified according to their structure. Based on the clinical trials that have been registered, very few of these natural or semi‐synthetic derivatives have been studied in humans. The review can help researchers understand the involved mechanisms and design new goal‐oriented studies for drug development against CNS malignancies.

show abstract

Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France)

Cited by 43 publications

References 49 publications

Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study

Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study

Nonmalignant meningioma and vestibular schwannoma incidence trends in the United States, 2004‐2017

A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

Contact Info

Product

Resources

About